Slide 1: 1H FY22 Results
1H FY22 Results Presenters 30 August 2022 Dr German Arango, CEO Reena Minhas, CFO
Slide 2: Agenda
Agenda 1H FY22 Results 1. IMEXHS Overview 2. 1H FY22 Results Overview 3. 1H FY22 Financials 4. Capital Raising 5. Outlook 2
Slide 3: Overview
imexHSs Overview
Slide 4: Business Highlights
Business Highlights Contracted Strong pipeline of Strong year-on-year Annualised Recurring opportunities incl. growth across all key Revenue of $20.5m, two material near- metrics up 61% year on year term opportunities Business to reach Disruptive, Founder led and underlying EBITDA proprietary, cloud
Slide 5: One Company with two businesses aimed at democratising access to medical expertise
One Company with two businesses aimed at democratising access to medical expertise Medical Imaging Software Radiology Services Provider of innovative, cloud-based, Outsourcing of imaging facilities AI medical imaging software and teleradiology to hospitals and solutions medical facilities 5
Slide 6: Software and Radiology Services footprint
Software Services 15 countries; 418 sites Colombia, Spain and Mexico 2,650+ radiologists 33 radiology centres 35 distributors in 15 countries 130+ in-house radiologists 37 engineers 6
Slide 7: 1H FY22 Results Overview
imexHs 1H FY22 Results Overview
Slide 8: 1H FY22 Operational Highlights
1H FY22 Operational Highlights • Awarded new expanded 3-year contract • IMEXHS Cloud (formerly AQUILA in the with major hospital group Colsubsidio, for Cloud) 140 contracts signed to date with the outsourcing of its entire radiology ARR of $2.8m services network at increased prices and additional se
Slide 9: Path to Profitability
Path to Profitability • Cost-out program aimed at getting to cash positive at the company level with both divisions profitable • Development is directed towards near term profitable outcomes • Sales capability directed towards immediate pipeline • Maintaining current high medical and customer servic
Slide 10: 1H FY22 Financial Highlights
1H FY22 Financial Highlights Sales Revenue Annual Recurring EBITDA Revenue (ARR)1 Up 83% yoy $9.5m Up 61% yoy $20.5m vs ($2.1m) in FY21 ($0.5m) Up 82% on a constant Up 60% on a constant currency basis3 currency basis Recurring Closing cash Underlying revenue EBITDA2 Up 91% yoy $9.3m vs $4.2m at 31 $
Slide 11: 1H FY22 Revenue and ARR Split
1H FY22 Revenue and ARR Split Medical • Software revenue primarily Radiology related to sales of AQUILA $M Software Total Services Enterprise Imaging • Radiology services includes Revenue 2.8 6.7 9.5 RIMAB along with other services related to outsourcing radiology ARR1 8.5 12.0 20.5 on-premise or re
Slide 12: Software: IMaging EXperts in Health Services
Software IMaging EXperts in Health Services • Multitenant Cloud based end to end software platform for medical imaging • Robust, stable, modular, flexible and intuitive • Web viewer rich in functionalities • Easily scalable from the smallest clinic to the largest hospital, and competitive across all
Slide 13: Software: IMEXHS Enterprise
Software IMEXHS Enterprise Number of Studies (m) • Enterprise imaging platform tailored to a customer’s specific needs +21% • Dedicated to large university hospitals 4.6m and multi-site healthcare organisations 3.8m • ARR of $5.7m at 30 June 2022 • Average contract length is 5 years • ~108 customers
Slide 14: Software: IMEXHS Cloud
Software IMEXHS Cloud Annualised Recurring Revenue (#039;000) and # of • Standardised radiology solution launched in contracts May 2020; unique and successful offering in an under-penetrated global market 2,800 • Provides small and medium-sized customers 2,700 with low-cost, rapidly deployed product 2,
Slide 15: Radiology Services
Radiology Services • Exclusive use of IMEXHS software drives efficiency and diagnostic capabilities • Outsourced radiology services for hospitals and other establishments • includes administration, technicians, enterprise software, training, equipment if required; radiologists located on premise and
Slide 16: 1H FY22 Financials
imexHs 1H FY22 Financials
Slide 17: Progress in ARR
Progress in ARR 201620172018201920202021 Jun-22 25 +61% vs pcp (+60% on a constant currency basis) 20 15 A$ Millions 10 Constant currency basis assumes that historic results are converted at the 30 Jun-22 exchange rate. This removes the impact of changes in currency rates and allows comparison of IM
Slide 18: Income Statement
Income Statement #039;000 1H FY22 1H FY21 Var Var % • Revenue of $9.5m, up 83% with 98% recurring revenue Revenue 9,462 5,159 4,303 83% • $2.8m from Software and Other revenue 133 74 59 81% • $6.7m from Radiology Services Total revenue 9,595 5,233 4,362 83% • Underlying EBITDA loss of ($0.4m) up Expens
Slide 19: Balance Sheet
Balance Sheet #039;000 Jun 22 Dec 21 Jun 21 • Closing cash balance of $0.9m as at Cash 856 4,186 8,342 30 June 2022 and Net Assets of Trade & other receivables 7,286 6,412 4,609 $15.4m Inventories 78 84 197 • Intangible assets include Goodwill of Current assets 8,220 10,682 13,148 $5.6m, $0.9m customer
Slide 20: Summary Cash Flow
Summary Cash Flow #039;000 1H FY22 1H FY22 • Closing cash balance of $0.9m as at 30 June 2022 Net cash used in operating activities (1,301) (1,566) • Net cash used in investing activities includes Net cash used in investing activities (1,544) (1,207) capitalised development costs of $0.9m and Net cash
Slide 21: Capital Raising
ime «Hs Capital Raising
Slide 22: Details and Progress of the Offer
Details and Progress of the Offer Offer Structure and • A fully underwritten capital raising of approximately $4.0m, comprising: Size • A fully underwritten Placement of $2.0m, consisting of two parts: • Tranche 1 – an institutional placement to raise approximately $1.0m (“Institutional Placement”);
Slide 23: Outlook
Outlook
Slide 24: FY22 Outlook
FY22 Outlook FY22 guidance • Initiatives to reach profitability and cashflow breakeven • Revenue between $18.0m to underway and maintaining the $20.5m (vs $13.4m in FY21) integrity of our 5-year strategic • Underlying1 EBITDA positive for framework 2022 (vs loss of $1.4m in FY21) • Strong and growin
Slide 25: Q&A
Q&A
Slide 26: Appendices
ime «Hs Appendices
Slide 27: 2025+ Endgame
2025+ Endgame Enterprise Imaging – Single – Medical Imaging platform RIS, PACS, VNA – – Cloud Technology Results Distribution Portal – Software – Multitenant Digital Pathology – Platform – DevOps Interoperability – – Onboarding automation Teleradiology – – SaaS / PaaS Business Model Multi-Department
Slide 28: 5-year Strategy Framework
5-year Strategy Framework 2026+ Cost saving initiatives announced will not have significant Harvesting impact on achieving milestones 10% Resource Allocation 2024 | 2025 Growing (Product Offering) IMEXHS Cloud 20% Resource Allocation • Single Unified Medical Imaging Single Software Software Platform
Slide 29: Disclaimer
Disclaimer The information contained in this Presentation or subsequently provided to the Recipient of this Presentation, whether orally or in writing by or on behalf of ImExHS Limited or its respective employees, agents or consultants (“Information”) is provided to the Recipient on the terms and co
Slide 30: 1H FY22 Results
1H FY22 Results 30 August 2022